SG11202106356QA - An optimized acceptor splice site module for biological and biotechnological applications - Google Patents

An optimized acceptor splice site module for biological and biotechnological applications

Info

Publication number
SG11202106356QA
SG11202106356QA SG11202106356QA SG11202106356QA SG11202106356QA SG 11202106356Q A SG11202106356Q A SG 11202106356QA SG 11202106356Q A SG11202106356Q A SG 11202106356QA SG 11202106356Q A SG11202106356Q A SG 11202106356QA SG 11202106356Q A SG11202106356Q A SG 11202106356QA
Authority
SG
Singapore
Prior art keywords
sequence
nucleotides
nucleic acid
acceptor splice
splice site
Prior art date
Application number
SG11202106356QA
Other languages
English (en)
Inventor
Stylianos Michalakis
Martin Biel
Elvir Becirovic
Original Assignee
Vigeneron Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigeneron Gmbh filed Critical Vigeneron Gmbh
Publication of SG11202106356QA publication Critical patent/SG11202106356QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202106356QA 2018-12-20 2019-12-19 An optimized acceptor splice site module for biological and biotechnological applications SG11202106356QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18214415 2018-12-20
PCT/EP2019/086454 WO2020127831A1 (en) 2018-12-20 2019-12-19 An optimized acceptor splice site module for biological and biotechnological applications

Publications (1)

Publication Number Publication Date
SG11202106356QA true SG11202106356QA (en) 2021-07-29

Family

ID=64755152

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106356QA SG11202106356QA (en) 2018-12-20 2019-12-19 An optimized acceptor splice site module for biological and biotechnological applications

Country Status (10)

Country Link
US (1) US12502438B2 (cg-RX-API-DMAC10.html)
EP (1) EP3898996A1 (cg-RX-API-DMAC10.html)
JP (2) JP7668737B2 (cg-RX-API-DMAC10.html)
KR (1) KR102938671B1 (cg-RX-API-DMAC10.html)
CN (1) CN113474460A (cg-RX-API-DMAC10.html)
AU (1) AU2019406702B2 (cg-RX-API-DMAC10.html)
CA (1) CA3122909A1 (cg-RX-API-DMAC10.html)
IL (1) IL284021B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202106356QA (cg-RX-API-DMAC10.html)
WO (1) WO2020127831A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898996A1 (en) * 2018-12-20 2021-10-27 Vigeneron GmbH An optimized acceptor splice site module for biological and biotechnological applications
CA3135490A1 (en) 2019-03-29 2020-10-08 Salk Institute For Biological Studies High-efficiency reconstitution of rna molecules
JP7866981B2 (ja) * 2020-07-14 2026-05-28 アビオナ・セラピュ―ティクス・インコーポレイテッド 多部分遺伝子送達のための組み換えアデノ随伴ウイルスベクター
US20230374476A1 (en) * 2021-02-05 2023-11-23 University Of Massachusetts Prime editor system for in vivo genome editing
EP4323391A4 (en) * 2021-04-15 2025-04-16 Tacit Therapeutics, Inc. HIGH-EFFICIENCY TRANS-SPLICING FOR TARGETED RNA SEQUENCE REPLACEMENT IN HUMAN CELLS
US20240216544A1 (en) * 2021-05-14 2024-07-04 Salk Institute For Biological Studies Methods and compositions for expression of editing proteins
CN120569476A (zh) 2022-11-30 2025-08-29 安铂生物公司 用于靶向反式剪接的方法和组合物
CN116463380A (zh) * 2023-03-30 2023-07-21 中国科学院深圳先进技术研究院 一种重组腺相关病毒载体组合物、外源基因表达系统及方法
US12655424B2 (en) 2024-02-05 2026-06-16 Amber Bio Inc. Methods and compositions for trans-splicing utilizing small nuclear RNAs and small nucleolar RNAs
CN121674392A (zh) * 2025-10-23 2026-03-17 中国科学院深圳先进技术研究院 反式剪接系统及其用途
US12686869B1 (en) 2026-01-23 2026-07-21 Amber Bio Inc. Methods and compositions for trans-splicing utilizing trifunctional elements

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US20030077754A1 (en) * 1995-12-15 2003-04-24 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
JP2009000120A (ja) * 1998-08-13 2009-01-08 Virxsys Corp スプライソソーム媒介rnaトランス−スプライシングにおける使用のための方法及び組成物
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
GB9906615D0 (en) 1999-03-22 1999-05-19 Oxford Biomedica Ltd Vector
CA2477295A1 (en) 2002-02-25 2003-09-04 Intronn, Inc. Trans-splicing mediated imaging of gene expression
US7968334B2 (en) 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
EP2486136B1 (en) 2009-10-08 2016-03-30 Association Institut de Myologie Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
JP2014525754A (ja) 2011-08-12 2014-10-02 バイレクシス コーポレイション アポトーシスを誘導するための組成物および方法
WO2013075008A1 (en) 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
DK2986635T3 (en) * 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
EP3393522B1 (en) * 2015-12-22 2021-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
AU2018350700B2 (en) 2017-10-16 2025-04-24 VeonGen Therapeutics GmbH AAV vectors
EP3898996A1 (en) * 2018-12-20 2021-10-27 Vigeneron GmbH An optimized acceptor splice site module for biological and biotechnological applications

Also Published As

Publication number Publication date
CN113474460A (zh) 2021-10-01
IL284021A (en) 2021-08-31
KR20210125472A (ko) 2021-10-18
US20220160898A1 (en) 2022-05-26
KR102938671B1 (ko) 2026-03-11
IL284021B1 (en) 2026-08-01
AU2019406702A1 (en) 2021-06-10
JP2025060848A (ja) 2025-04-10
JP7668737B2 (ja) 2025-04-25
WO2020127831A1 (en) 2020-06-25
CA3122909A1 (en) 2020-06-25
EP3898996A1 (en) 2021-10-27
AU2019406702B2 (en) 2025-12-18
US12502438B2 (en) 2025-12-23
JP2022515606A (ja) 2022-02-21

Similar Documents

Publication Publication Date Title
SG11202008115UA (en) Waveguide element and waveguide stack for display applications
EP3580597A4 (en) OPTICS, DEVICE AND SYSTEM FOR TESTING
EP3345040A4 (en) DIFFERENTIAL REAR LIGHTS INDICATOR AND SYSTEM
IL284021A (en) An optimized acceptor splice site module for biological and biotechnological applications
EP3373058A4 (en) Lens driving device, and camera module and optical instrument comprising same
EP3902000A4 (en) BACKLIGHT MODULE
EP3321565A4 (en) BACKLIGHT MODULE AND DISPLAY DEVICE
EP3133440A4 (en) Camera module and optical instrument
EP3249451A4 (en) Liquid crystal element, deflection element, liquid crystal module, and electronic device
EP3243094A4 (en) Polarization-mixing light guide and multibeam grating-based backlighting using same
EP3373066A4 (en) Lens driving device and camera module including same
EP3396762A4 (en) FUEL CELL SYSTEM AND METHOD FOR CONTROLLING THIS SYSTEM
EP3808835A4 (en) CELL CULTURE SYSTEM AND CELL CULTURE PROCESS
DK3566041T3 (da) Modulære optiske analytiske systemer og fremgangsmåder
EP3512017A4 (en) FUEL CELL SYSTEM AND METHOD FOR CONTROLLING THEREOF
EP3607373A4 (en) OPTICAL TERMINATION AND SPLICE MODULE
EP3287690A4 (en) BACKLIGHT MODULE AND DISPLAY DEVICE
EP3780299A4 (en) Laser module and laser device
EP3534447A4 (en) FUEL CELL MODULE AND FUEL CELL DEVICE
DK3442093T3 (da) Opladningsstyreanordning og strømadapter
EP3904952A4 (en) DIRECT TYPE BACKLIGHT MODULE AND DISPLAY
EP3697889A4 (en) MULTI-AXIS MECHANICAL STIMULATION SYSTEMS AND INCUBATORS
EP3641162A4 (en) METHOD AND DEVICE FOR COMPENSATING OPTICAL PERFORMANCE
EP3793739A4 (en) PORTABLE MICROFLUIDIC SYSTEM FOR BIOLOGICAL AND ANALYTIC TESTING
EP3677954A4 (en) BACKLIGHT MODULE AND DISPLAY DEVICE